MAPT and Alzheimer disease: To specifically replicate the role of tau pathology in hubs in subjects with a clinical disease onset before the age of 65, we encourage future studies to assess whether our results can be replicated in dedicated early-onset AD datasets such as the LEADs cohort (https://clinicaltrials.gov/ct2/show/NCT03507257), once sufficient data become available.